Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide + isatuximab + dexamethasone for early-progressing multiple myeloma
ACTRN12621001037897Phase 2Recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide, isatuximab and dexamethasone in multiple myeloma (MM), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Best response to treatment. Started May 2023; status: recruiting.
02
Drugs
iberdomideisatuximabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12621001037897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001037897.